In our previous work, it has been indicated that agents targeting aerobic glycolysis enzymes, such as aspirin (targeting PFKFB3) [24], sodium butyrate (targeting HK2) [6], proanthocyanidin B2 (targeting PKM2) [20], and EGCG (targeting PFKL) [13], could synergistically enhance the therapeutic effect of sorafenib on HCC. Here, PFKL is linked to hepatocellular carcinoma.